We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




POC Oral Swab Test to Increase Chances of Pregnancy in IVF

By LabMedica International staff writers
Posted on 13 May 2025

Approximately 15% of couples of reproductive age experience involuntary childlessness. More...

A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to increase in the future. In vitro fertilization (IVF) treatment involves stimulating the woman’s ovaries to mature multiple eggs, which are then retrieved, fertilized with sperm in the lab, and later re-implanted into the uterus. There are two main types of hormone treatments available for egg maturation: biological and synthetic. However, while hormone therapy is essential, it carries risks of severe side effects, sometimes leading to the need for intensive care, and many IVF attempts are unsuccessful. One key factor influencing the success of IVF is the choice of hormone therapy, but healthcare providers often face the challenge of selecting the most effective treatment for each woman. Now, a simple oral swab test conducted before IVF could ensure higher success rates.

To identify the most effective hormone treatment for each individual, researchers at Lund University (Lund, Sweden) turned to genetics. Their study involved 1,466 women undergoing IVF treatment, excluding those with endometriosis or polycystic ovary syndrome (PCOS). Among the participants, 475 were randomly assigned to receive one of two hormone treatments, while the remaining participants served as controls. The researchers focused on a gene involved in fertilization, which regulates the action of follicle-stimulating hormone (FSH), a crucial hormone for egg maturation, and mapped this gene through gene sequencing.

The findings, published in Frontiers in Endocrinology, revealed that women carrying a specific variant of the FSH receptor (FSHR) gene, which regulates FSH activity, responded more favorably to biological hormone treatment. Meanwhile, other women benefited more from synthetic hormone treatments. The researchers believe that by understanding a woman’s genetic profile in advance, the likelihood of successful pregnancies can be significantly increased. However, gene mapping is both expensive and time-consuming. To address this, the researchers have developed a simple oral swab test that can quickly determine the most suitable hormone therapy within an hour, with the results indicated by a color change to pink or yellow, making it easy to interpret.

“Our hope is that this will reduce the risk of suffering for women, increase the number of successful treatments and cut costs for taxpayers. Our goal is for the test to be available by the start of 2026,” said Yvonne Lundberg Giwercman, professor at Lund University who led the research.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Drug Testing Assays
Atellica DT 250 Analyzer
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The screening algorithm incorporates two plasma biomarkers: amyloid-beta ratio and p-tau217, which together help indicate brain amyloid burden (Image Credit: Shutterstock)

Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening

Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.